Pacific Edge Limited (PFGTF) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Pacific Edge Limited, a leader in cancer diagnostics, announced a steady financial performance for the first half of 2024, despite uncertainties surrounding Medicare. The company is anticipating potential growth catalysts, including a favorable Medicare policy decision and new pricing recommendations for its Cxbladder tests. While revenue slightly declined compared to the previous year, the strategic focus remains on profitable markets and the economic value of its diagnostic tools.
For further insights into PFGTF stock, check out TipRanks’ Stock Analysis page.
